News Articles
Latest articles, insights, and updates from the blog.
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.
Foundation Reviews Ketamine Depression Treatment Facts
MedShadow Foundation publishes educational overview of ketamine as antidepressant treatment. What patients need to know about efficacy, safety, and access.
9/11 Widow's Depression Breakthrough Highlights Ketamine
A 9/11 survivor's successful ketamine treatment for treatment-resistant depression offers hope and insights for trauma-related mental health care.
Expert Highlights Critical Ketamine Patient Considerations
Dr. Benjamin Brody discusses essential patient considerations for ketamine therapy at major psychiatric conference, covering safety protocols and clinical best practices.
Stanford Study: Drug Combo Extends Ketamine Anti-Suicide Effects
Stanford researchers report first drug combination to extend ketamine's rapid anti-suicide effects, potentially changing treatment protocols.
Boston Ketamine Clinics: A Window Into Real-World Use
CBS News spotlights Boston ketamine clinics treating mental health conditions. What real-world patient outcomes reveal about low-dose ketamine therapy.
What a Year of Experimental Depression Treatment Reveals
A Guardian journalist spent a year testing ketamine, TMS, and gut therapy for depression. Here's what their experience reveals about low-dose ketamine.
FDA Clears MIND1 Trial: NRX-101 Plus Robotic TMS for Suicidality
The FDA has cleared the MIND1 trial testing NRX-101 plus robotic TMS for suicidality in treatment-resistant depression. What it means for ketamine patients.
CBT After Esketamine Cuts Relapse Risk, Trial Finds
The CBT-ENDURE trial shows 16 weeks of CBT after esketamine significantly reduces relapse risk and suicidal ideation. What it means for ketamine patients.
Esketamine Safety Protocols: What Clinicians Now Emphasize
A new clinical overview on esketamine nasal spray details REMS requirements, two-hour monitoring, and vitals tracking. Here's what it means for ketamine patients.
When to Switch or Stay: NMDA Therapy Discontinuation Rates
New analysis reveals why patients stop NMDA receptor antagonist therapy, and what discontinuation data means for low-dose ketamine monitoring and dosing decisions.
What Dropout Rates Reveal About NMDA Therapy Tolerability
New psychiatric guidance examines why patients stop NMDA antagonist therapy and what side effect data means for low-dose ketamine treatment decisions.
When Ketamine Side Effects Signal Time to Adjust Dose
New clinical analysis examines why patients stop NMDA antagonist therapy, and how smarter dose management may improve remission outcomes in TRD.